Table 1.
Association of BRAFV600E or the TERT promoter mutations with clinicopathological characteristics of PTC patients
| Variables |
BRAF mutation, n (%)
|
p-value |
TERT promoter mutations, n (%)
|
p-value | ||
|---|---|---|---|---|---|---|
| Wild-type, n=72 | V600E mutation, n=270 | Wild-type, n=330 | Mutation, n=12 | |||
| Age, years (mean ± SD) | 39.1±11.9 | 43.2±13.4 | 0.018 | 41.5±12.6 | 65.1±9.7 | <0.001 |
| Sex (F/M, % male) | 60/12 (16.6) | 183/87 (32.2) | 0.010 | 232/98 (29.6) | 11/1 (8.3) | 0.109 |
| Tumor size (mean ± SD) | 14.6±9.1 | 15.4±9.7 | 0.51 | 14.4±8.8 | 26.2±12.6 | <0.001 |
| Microcarcinoma | 25 (34.7) | 108 (40.0) | 0.51 | 133 (40.3) | 0 (0) | 0.005 |
| Multifocality | 14 (19.4) | 83 (30.7) | 0.059 | 92 (27.8) | 5 (41.6) | 0.29 |
| HT | 22 (30.5) | 40 (14.8) | 0.002 | 61 (18.4) | 1 (8.3) | 0.37 |
| ETE | 19 (26.3) | 83 (30.7) | 0.47 | 92 (27.8) | 10 (83.3) | <0.001 |
| CLNM | 50 (69.4) | 175 (64.8) | 0.46 | 215 (65.1) | 10 (83.3) | 0.19 |
| LLNMa | 40 (59.7) | 121 (47.4) | 0.074 | 152 (49.0) | 9 (75.0) | 0.078 |
| LNMN >5 | 27 (55.2) | 85 (33.3) | 0.33 | 106 (31.8) | 6 (50.0) | 0.19 |
| No. of LNs harvested | 34.9±15.6 | 36.3±18.5 | 0.577 | 35.7±17.7 | 44.3±24.1 | 0.104 |
| No. of LNs involved | 6.2±8.4 | 4.9±6.2 | 0.130 | 5.1±6.7 | 6.6±7.4 | 0.447 |
| TNM stageb | ||||||
| I | 67 | 232 | 296 | 3 | ||
| II | 6 | 26 | 28 | 4 | ||
| III | 0 | 7 | 4 | 3 | ||
| IV | 0 | 5 | 0.069 | 2 | 3 | <0.001 |
Notes:
a
The percentage is only calculated in patients with lateral neck dissection;
b
calculations for stage (I + II) vs (III + IV).
Abbreviations: CLNM, central lymph node metastasis; ETE, extrathyroidal extension; HT, Hashimoto thyroiditis; LLNM, lateral lymph node metastasis; LNMN, numbers of lymph node metastases >5; LN, lymph nodes; PTC, papillary thyroid carcinoma; TNM, tumor/node/metastasis.